Goldman Sachs Group Inc. lifted its holdings in shares of Exactech, Inc. (NASDAQ:EXAC) by 166.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,185 shares of the medical equipment provider’s stock after acquiring an additional 23,837 shares during the quarter. Goldman Sachs Group Inc. owned about 0.26% of Exactech worth $1,888,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of EXAC. Water Island Capital LLC acquired a new position in shares of Exactech during the 4th quarter valued at $26,772,000. Gabelli Funds LLC lifted its holdings in shares of Exactech by 138.7% during the 4th quarter. Gabelli Funds LLC now owns 701,748 shares of the medical equipment provider’s stock valued at $34,701,000 after acquiring an additional 407,724 shares in the last quarter. Kennedy Capital Management Inc. acquired a new position in shares of Exactech during the 4th quarter valued at $17,938,000. Pentwater Capital Management LP acquired a new position in shares of Exactech during the 4th quarter valued at $12,363,000. Finally, Gamco Investors INC. ET AL lifted its holdings in shares of Exactech by 24.8% during the 4th quarter. Gamco Investors INC. ET AL now owns 764,508 shares of the medical equipment provider’s stock valued at $37,805,000 after acquiring an additional 151,991 shares in the last quarter. Institutional investors and hedge funds own 61.22% of the company’s stock.
Shares of EXAC stock opened at $49.25 on Tuesday. Exactech, Inc. has a 12 month low of $23.75 and a 12 month high of $50.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09.
Several research firms recently weighed in on EXAC. BidaskClub lowered shares of Exactech from a “hold” rating to a “sell” rating in a report on Thursday, February 15th. Zacks Investment Research upgraded shares of Exactech from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. One analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. Exactech currently has a consensus rating of “Hold” and an average target price of $49.00.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/17/goldman-sachs-group-inc-acquires-23837-shares-of-exactech-inc-exac.html.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
Receive News & Ratings for Exactech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech and related companies with MarketBeat.com's FREE daily email newsletter.